In the version of the article, “Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes: An Individual Patient–Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials,” by Mehta et al that was posted online on October 27, 2008 (DOI: 10.1161/CIRCULATIONAHA.108.789479), an error occurred. In Table 2, row 16, the values for “Death, MI, or stroke” were inadvertently omitted. These values, moving left to right, are “1649 (12.8)” —n (%) for heparin, “14898 (11.5)” —n (%) for fondaparinux, “0.90” —HR, 0.84-0.96—95% CI, and “0.002”—P. The values have been included in the final print version of the article in the August 11, 2008, issue of the journal (Circulation. 2008;118:2038–2046) and in the current online version. The authors regret the error.